Community Practice Connections(TM): Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

Target Audience
This educational activity is directed toward medical hematologists and other health care professionals interested in the latest advances in the treatment of patients with CAD. Fellows, researchers, primary care physicians, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic diseases are also invited to participate.
Activity Overview
Cold agglutinin disease (CAD) is a rare autoimmune disease in which exposure to cold temperatures may trigger hemolysis leading to anemia. Symptoms may arise suddenly and can range in occurrence and severity; this can be debilitating and potentially life-threatening. More than half of the affected patients may require transfusions and a majority requires treatment; however, options are limited, and none are specifically approved for CAD. However, novel complement-directed therapies are in development, which hold promise for this autoimmune hemolytic anemia.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the live virtual symposium held on June 10, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with CAD, while placing recent clinical trial data into a clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learnings for those who did.